Group 1 - The board of directors of Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd. held a meeting on August 22, 2025, with all 9 directors present, confirming the legality and validity of the meeting procedures [1] - The company’s 2025 semi-annual report was approved, stating that the report accurately reflects the financial and operational status of the company for the first half of 2025 [2] - The board unanimously agreed to the proposal regarding the timely and accurate disclosure of the use of raised funds, confirming no violations in the use of these funds [2] Group 2 - The company decided to make provisions for asset impairment based on prudent principles, ensuring that the provisions accurately reflect the asset status in compliance with accounting standards [3] - A new action plan titled "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" for 2025 was approved, aligning with national policies aimed at enhancing the quality of listed companies [3]

Core Viewpoint - Lino Pharmaceutical Packaging (301188.SZ) is expanding its business by investing in a New Third Board company, Changyang Co., to enhance its product offerings and achieve resource sharing amid declining performance in its core business [1][2]. Financial Performance - In the first half of 2025, Lino Pharmaceutical reported revenue of 499 million yuan, a year-on-year decrease of 11.07%, and a net profit of 40.97 million yuan, down 20.12% [1][6]. - The company experienced a decline in revenue and net profit in 2022 and 2023, with revenues of 822 million yuan and 947 million yuan, and net profits of 117 million yuan and 65.92 million yuan, respectively [6][7]. - For 2024, Lino Pharmaceutical expects revenue to reach 1.081 billion yuan, a year-on-year increase of 14.09%, with net profit slightly increasing by 0.23% [6]. Investment Details - Lino Pharmaceutical plans to acquire 30% of Changyang Co. by purchasing 34.0465 million shares for 84 million yuan, which will not change the control of Changyang [2][3]. - The acquisition is aimed at integrating resources and expanding product categories to provide one-stop procurement for downstream clients [3]. Market Conditions - The decline in performance is attributed to weak demand in the pharmaceutical terminal market, price reductions, and increased expenses due to various factors, including national healthcare reforms and centralized procurement policies [7]. - The company has faced rising costs for raw materials due to tariff impacts in the second quarter [7]. Shareholder Activity - Recently, major shareholders from the Fosun Group announced plans to reduce their holdings by up to 3% within three months, which may affect market sentiment [1][8].

Core Viewpoint - Lino Pharmaceutical Packaging's stock price has declined significantly, reflecting challenges in revenue and profit, while the company is actively pursuing growth through acquisitions and joint ventures [1] Financial Performance - As of August 21, 2025, Lino Pharmaceutical Packaging's stock price is 19.86 CNY, down 1.32 CNY or 6.23% from the previous trading day [1] - In the first half of 2025, the company reported revenue of 499 million CNY, a year-on-year decrease of 11.07% [1] - The net profit attributable to shareholders was 40.97 million CNY, down 20.12% year-on-year [1] - R&D expenses increased by 7.19% to 16.03 million CNY, while sales expenses rose by 21.68% to 26.71 million CNY [1] Business Strategy - The company is expanding its business scope through acquisitions and joint ventures, aiming to establish a "glass + plastic" one-stop service capability [1] - Lino Pharmaceutical Packaging plans to jointly invest 92.65 million CNY with its controlling shareholder, Lino Group, to establish a joint venture [1] - The company intends to acquire a 30% stake in Suzhou Chuangyang New Materials Technology Co., Ltd. for 84 million CNY [1] Market Activity - On August 21, 2025, the net outflow of main funds from Lino Pharmaceutical Packaging was 59.91 million CNY, accounting for 1.26% of its market capitalization [1] - Over the past five days, the net outflow of main funds totaled 253.35 million CNY, representing 5.34% of its market capitalization [1]

Core Viewpoint - Shandong Linuo Pharmaceutical Packaging Co., Ltd. (301188.SZ) reported steady growth in its half-year performance for 2025, with revenue of 499 million yuan and a net profit of 40.97 million yuan, while enhancing its production capacity for borosilicate pharmaceutical glass and pursuing external growth strategies through acquisitions and joint ventures [1][2]. Group 1: Financial Performance - The company achieved an operating income of 499 million yuan and a net profit attributable to shareholders of 40.97 million yuan during the reporting period [1]. - Total assets at the end of the period amounted to 2.537 billion yuan [1]. Group 2: Production Capacity Enhancement - The production capacity for borosilicate pharmaceutical glass has been further increased, with the first furnace of the lightweight pharmaceutical molded glass bottle project having been ignited and put into production in February 2025 [2]. - The company is continuously increasing its production equipment for borosilicate tubular bottles to meet the growing demand from downstream customers, thereby expanding its market share in the pharmaceutical packaging sector [2]. Group 3: External Growth Strategies - The company has identified external growth as a key strategy for 2025, focusing on investing in quality enterprises in the pharmaceutical packaging field to broaden its product range [3]. - On August 19, the board approved a cash acquisition of 30% equity in Suzhou Chuangyang New Materials Technology Co., Ltd. for 84 million yuan, which will enhance the company's service capabilities by integrating plastic packaging materials with its existing glass offerings [3]. - A joint venture with Linuo Group is planned, with an investment of 92.65 million yuan to establish Linuo Innovation Technology (Shanghe) Co., Ltd., aimed at creating a high-end pharmaceutical packaging industry platform [3]. Group 4: Global Expansion - The company is focusing on global expansion, having conducted market assessments in regions such as Saudi Arabia, Brazil, and Southeast Asia, and signed a cooperation investment agreement with SANTISA in March 2025 [4]. Group 5: Financial Stability and Future Prospects - The company reported a net cash outflow from operating activities of 96.05 million yuan, primarily due to increased raw material inventory and slower sales collection [5]. - With a cash balance of 537 million yuan and a low debt ratio of 37.1%, the company has sufficient leverage for future expansion [5]. - The growing demand for high-quality packaging materials in the pharmaceutical industry, particularly for borosilicate glass, positions the company to strengthen its leading market position [5].

证券代码：301188 证券简称：力诺药包 公告编号：2025-065 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 第四届董事会第十二次会议决议公告 下简称"《公司法》"）等法律法规和《公司章程》的有关规定，会议合法、有 效。 二、董事会会议审议情况 根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规 以及《公司章程》的规定，公司编制了《2025 年半年度报告》全文及摘要。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《2025 年年半年度报告》（公告编号：2025-067）及《2025 年半年度报告摘要》（公 告编号：2025-068）。《2025 年半年度报告摘要》同时刊登在《中国证券报》 《上海证券报》《证券时报》《证券日报》上。 本议案已经第四届董事会审计委员会第八次会议审议通过。 议案表决结果：同意票 7 票，反对票 0 票，弃权票 0 票。 报告>的议案》 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大 ...

Core Viewpoint - The supervisory board of Shandong Linuo Pharmaceutical Packaging Co., Ltd. has confirmed the legality and accuracy of the company's 2025 semi-annual report and related financial documents, ensuring compliance with relevant regulations and reflecting the company's actual situation [1][2][3]. Meeting Details - The 11th meeting of the 4th supervisory board was held on August 8, 2025, with all three supervisors present, either in person or via telecommunication, confirming the meeting's legality and effectiveness [1]. Financial Report Review - The supervisory board reviewed the 2025 semi-annual report and found that the procedures for its preparation and review complied with legal and regulatory requirements, with no false records or significant omissions [1][2]. Fund Usage Compliance - The board confirmed that the use of raised funds during the first half of 2025 adhered to the relevant regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange, with no violations noted [2][3]. Change in Fund Usage - The supervisory board approved a change in the use of part of the raised funds, stating that the decision aligns with the company's current needs and will enhance the efficiency of fund utilization, benefiting the company and its shareholders [3][4]. Acquisition and Investment - The board agreed on a transaction based on the company's business development needs, which aims to integrate resources with Suzhou Chuangyang New Materials Technology Co., Ltd., ensuring reasonable pricing and no significant impact on daily operations [3][4]. Risk Management Enhancement - The board supported the purchase of directors and officers liability insurance, which is expected to optimize the company's risk management system and promote responsible conduct among senior management [4][5].

证券代码：301188 证券简称：力诺药包 公告编号：2025-074 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日召开 的第四届董事会第十二次会议决议，公司董事会定于 2025 年 9 月 5 日召开 2025 年第二 次临时股东会。现将有关事项通知如下： 一、会议召开基本情况 章、规范性文件和《公司章程》的有关规定。 现场会议召开时间：2025 年 9 月 5 日（星期五）14:50 网络投票时间： 其中，通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时 间为：2025 年 9 月 5 日 9:15-9:25、9:30—11:30，13:00—15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为：2025 年 9 月 5 日 9:15-15:00。 （1）现场投票：股东本人出席现场会议或者通过授权他人出席现场会议； （2）网络投票：本次股东会将通过深圳证券交易所交易 ...

Group 1 - The company plans to purchase Directors, Supervisors, and Senior Management Liability Insurance (D&O Insurance) to enhance its risk management system and protect the rights of its executives and shareholders, especially minority investors [1][2] - The board of directors has proposed to authorize the management to handle the purchase of the D&O Insurance, including determining the insured parties, insurance company, compensation limits, premiums, and other related matters [2] - The proposal for the D&O Insurance was discussed in the board and supervisory meetings held on August 19, 2025, where all directors and supervisors abstained from voting due to being insured parties, leading to the proposal being submitted to the upcoming extraordinary general meeting for approval [1][2]

Summary of Key Points Core Viewpoint The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., has decided to change the use of part of the raised funds from its convertible bond issuance to better align with its current development needs and strategic planning. Group 1: Fundraising Overview - The company issued 5 million convertible bonds with a total fundraising amount of 500 million RMB, netting 491.44 million RMB after deducting fees [1][2] - The original project for the raised funds was the industrialization of lightweight pharmaceutical molded glass bottles, with a total investment of 641.87 million RMB [2][4] - As of August 10, 2025, 126.05 million RMB of the raised funds had been utilized, leaving an unused amount [2][4] Group 2: Change in Fund Usage - The company plans to reallocate 154 million RMB from the original project to two new projects: acquiring a 30% stake in Chuangyang Co. and the second phase of the high-end pharmaceutical packaging project [2][5] - The new projects include an investment of 84 million RMB for the acquisition and 70 million RMB for the high-end packaging project [2][5] Group 3: Rationale for Change - The original project faced delays due to late delivery of construction facilities and lengthy customer certification processes, leading to a reduced funding requirement [4][5] - The company received a government subsidy of 89.58 million RMB for the original project, further decreasing the need for raised funds [4][5] Group 4: New Investment Projects - The acquisition of a 30% stake in Chuangyang Co. aims to enhance the company's product offerings and market share in pharmaceutical packaging [5][8] - The second phase of the high-end packaging project focuses on RTU (Ready-to-Use) packaging and pre-filled syringes, with a total investment of 383.37 million RMB [9][10] - The project is expected to have a payback period of 6.82 years and an internal rate of return of 16.37% [9] Group 5: Strategic Importance - The new projects align with the growing demand for high-quality pharmaceutical packaging driven by trends in the pharmaceutical industry [10][11] - The company aims to transition from a traditional pharmaceutical glass manufacturer to a diversified high-end packaging solution provider [10][12] - The strategic shift is supported by national policies promoting the development of the pharmaceutical packaging industry [13][14] Group 6: Approval Process - The board of directors and the supervisory board have approved the change in fund usage, ensuring compliance with relevant regulations [16][17] - The independent directors also confirmed that the decision aligns with the company's interests and does not harm shareholder value [17][18]

山东力诺医药包装股份有限公司 第四届董事会独立董事 2025 年第五次专门会议审核意见 根据《中华人民共和国公司法》 《深圳证券交易所创业板股票上市规则》 《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律、法规和规范性文件以及《公司章程》的有关规定，山东力诺医药包装股份有 限公司（以下简称"公司"）独立董事召开了第四届董事会独立董事 2025 年第五 次专门会议，审议通过了《关于公司<2025 年半年度募集资金存放与使用情况的 专项报告>的议案》《关于变更部分募集资金用途的议案》《关于拟对外投资购买 股权的议案》 《关于购买董监高责任险的议案》 经核查，我们认为：本次交易是基于公司业务发展需要，为实现公司长远发 展战略规划而做出的整体安排，有利于整合公司与苏州创扬新材料科技股份有限 公司的资源和优势，实现资源共享、共同发展。本次交易风险可控，投资资金来 源于公司募集资金，不会影响公司生产经营活动和现金流的正常运转，不会对公 司未来财务及经营状况产生重大影响，不存在损害上市公司及股东利益的情形。 我们一致同意本次对外投资购买股权事项。 四、关于购买董监高责任险的审核意见 经核 ...